Phase 3 Study of KHK7580

PHASE3CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

September 28, 2015

Primary Completion Date

December 6, 2016

Study Completion Date

December 28, 2016

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG

KHK7580

Oral administration

Trial Locations (1)

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin, Tokyo

All Listed Sponsors

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT02549404 - Phase 3 Study of KHK7580 | Biotech Hunter | Biotech Hunter